{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:36:55Z","timestamp":1790095015863,"version":"4.0.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Yasha Najafi MSc"},{"name":"UCB Pharma in accordance with Good Publication Practice"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with psoriasis require long-term management; therefore, understanding the long-term safety of new treatments, such as bimekizumab (BKZ), is crucial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate BKZ\u2019s 3-year safety profile in patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Three years of safety data were pooled from three phase III trials (BE VIVID, BE READY and BE SURE) and their ongoing open-label extension (BE BRIGHT). Treatment-emergent adverse events (TEAEs) are reported using exposure-adjusted incidence rates (EAIRs) per 100 patient-years (PY).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 1495 patients received at least one BKZ dose; total BKZ exposure was 3876.4 PY. The overall EAIR of TEAEs was 175.5\/100 PY and decreased with longer exposure to BKZ. The most commonly reported TEAEs were nasopharyngitis, oral candidiasis and upper respiratory tract infection (EAIRs of 15.0\/100 PY, 10.1\/100 PY and 6.5\/100 PY, respectively); 99.3% of oral candidiasis events were mild or moderate in severity, none were serious and few led to discontinuation. EAIRs of other TEAEs of interest were low, including serious infections (1.2\/100 PY), adjudicated inflammatory bowel disease (0.2\/100 PY) and laboratory elevations in aspartate aminotransferase or alanine aminotransferase (&amp;gt; 5 \u00d7 upper limit of normal: 0.6\/100 PY).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In these analyses pooled across 3\u2005years, no new safety signals were observed with longer exposure to BKZ. The vast majority of oral candidiasis events were mild or moderate in severity, as reported previously.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad429","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T19:12:50Z","timestamp":1699729970000},"page":"477-485","source":"Crossref","is-referenced-by-count":30,"title":["Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3\u2005years of treatment in randomized phase III trials"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-0292","authenticated-orcid":false,"given":"Kenneth B","family":"Gordon","sequence":"first","affiliation":[{"name":"Medical College of Wisconsin , Milwaukee, WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard G","family":"Langley","sequence":"additional","affiliation":[{"name":"Dalhousie University , Halifax, NS , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust , Manchester , UK"},{"name":"NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[{"name":"Tokyo Medical University , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine , Indianapolis, IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Peterson","sequence":"additional","affiliation":[{"name":"UCB Pharma , Morrisville, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Madden","sequence":"additional","affiliation":[{"name":"UCB Pharma , Morrisville, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"de Cuyper","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Davies","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck , L\u00fcbeck , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"2024090210042782900_ljad429-B1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2024090210042782900_ljad429-B2","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2024090210042782900_ljad429-B3","doi-asserted-by":"crossref","first-page":"e027535","DOI":"10.1136\/bmjopen-2018-027535","article-title":"Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry","volume":"9","author":"Strober","year":"2019","journal-title":"BMJ Open"},{"key":"2024090210042782900_ljad429-B4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024090210042782900_ljad429-B5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: a prospective population-based cohort study","volume":"78","author":"Wan","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024090210042782900_ljad429-B6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archdermatol.2009.48","article-title":"Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses","volume":"145","author":"Qureshi","year":"2009","journal-title":"Arch Dermatol"},{"key":"2024090210042782900_ljad429-B7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2024090210042782900_ljad429-B8","first-page":"891","article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis","volume":"146","author":"Kurd","year":"2010","journal-title":"Arch Dermatol"},{"key":"2024090210042782900_ljad429-B9","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jaad.2009.09.053","article-title":"Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation","volume":"63","author":"Bremmer","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2024090210042782900_ljad429-B10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"2024090210042782900_ljad429-B11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2024090210042782900_ljad429-B12","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"2024090210042782900_ljad429-B13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"2024090210042782900_ljad429-B14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"2024090210042782900_ljad429-B15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of \u00adixekizumab through 5\u2005years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther"},{"key":"2024090210042782900_ljad429-B16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jdv.16124","article-title":"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease","volume":"34","author":"Reich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024090210042782900_ljad429-B17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","article-title":"Maintenance of clinical response and consistent safety profile with up to 3\u2005years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials","volume":"82","author":"Reich","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024090210042782900_ljad429-B18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024090210042782900_ljad429-B19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5\u2005years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther"},{"key":"2024090210042782900_ljad429-B20","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"2024090210042782900_ljad429-B21","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2024090210042782900_ljad429-B22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024090210042782900_ljad429-B23","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"2024090210042782900_ljad429-B24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"2024090210042782900_ljad429-B25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2024090210042782900_ljad429-B26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"2024090210042782900_ljad429-B27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2024090210042782900_ljad429-B28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.","volume":"188","author":"Strober","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024090210042782900_ljad429-B29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024090210042782900_ljad429-B30"},{"key":"2024090210042782900_ljad429-B31","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"2024090210042782900_ljad429-B32","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the PSOriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"2024090210042782900_ljad429-B33","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","article-title":"Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort","volume":"65","author":"Wakkee","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2024090210042782900_ljad429-B34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis","volume":"45","author":"Kamata","year":"2018","journal-title":"J Dermatol"},{"key":"2024090210042782900_ljad429-B35","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the PSOriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2024090210042782900_ljad429-B36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2024090210042782900_ljad429-B37","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024090210042782900_ljad429-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2013.58","article-title":"IL-17 cytokines in immunity and inflammation","volume":"2","author":"Jin","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"2024090210042782900_ljad429-B39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2024090210042782900_ljad429-B40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40257-016-0206-4","article-title":"A clinician\u2019s guide to the diagnosis and treatment of candidiasis in patients with psoriasis","volume":"17","author":"Armstrong","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"2024090210042782900_ljad429-B41","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/jid.2015.144","article-title":"IL-23\/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies","volume":"135","author":"Blauvelt","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2024090210042782900_ljad429-B42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jdermsci.2020.12.003","article-title":"Blockade of the IL-17 \u00adsignaling pathway increased susceptibility of psoriasis patients\u00a0to\u00a0superficial fungal infections","volume":"101","author":"Hiruma","year":"2021","journal-title":"J Dermatol Sci"},{"key":"2024090210042782900_ljad429-B43","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s13555-022-00687-0","article-title":"A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb"},{"key":"2024090210042782900_ljad429-B44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2024090210042782900_ljad429-B45","first-page":"75","article-title":"Psoriasis and alcohol","volume-title":"Psoriasis (Auckl)","author":"Svanstr\u00f6m","year":"2019"},{"key":"2024090210042782900_ljad429-B46","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-2-1","article-title":"Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors","volume":"9","author":"Fieldhouse","year":"2020","journal-title":"Drugs Context"},{"key":"2024090210042782900_ljad429-B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-019-1067-0","article-title":"Crohn\u2019s-like disease in a patient exposed to anti-interleukin-17 blockade (ixekizumab) for the treatment of chronic plaque psoriasis: a case report","volume":"19","author":"Smith","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"2024090210042782900_ljad429-B48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjd.14528","article-title":"Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"key":"2024090210042782900_ljad429-B49","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis","volume":"134","author":"Dowlatshahi","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2024090210042782900_ljad429-B50","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"2024090210042782900_ljad429-B51","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/0141076814522033","article-title":"Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage","volume":"107","author":"Singhal","year":"2014","journal-title":"J R Soc Med"},{"key":"2024090210042782900_ljad429-B52"},{"key":"2024090210042782900_ljad429-B53","first-page":"571","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the PSOriasis Longitudinal Assessment and Registry (PSOLAR). Errata","volume":"19","author":"Papp","year":"2020","journal-title":"J Drugs Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad429\/56699390\/ljad429.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/4\/477\/58993204\/ljad429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/4\/477\/58993204\/ljad429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T12:42:08Z","timestamp":1725280928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/4\/477\/7405373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,10]]},"published-print":{"date-parts":[[2024,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad429","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,11,10]]}}}